Loading…
← CockpitCompetitor Analysis › 001060.KS JW Pharmaceutical CorporationOpen in the cockpit ↗

JW Pharmaceutical Corporation001060.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum neutral 57
Mkt cap
$423M
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$513,319
20-day average traded
Fwd P/E
6.3×
forward earnings
ROIC−WACC
+11.7 pp
WACC 6.9%
Hurdle
-23 pp
Req g minus delivered
Next earnings
125 days
23 Mar 2027
Close · KRW₩23,200
1D+0.9%
1W-1.7%
1M-7.4%
3M-19.6%
6M-25.9%
YTD-9.0%
1Y-7.9%
ATR %3.5%
52w lowhigh40.9% off high

What JW Pharmaceutical does

Employees: 1,106

JW Pharmaceutical at a glance

Size JW Pharmaceutical (001060.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $423M, the 387th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩23,200 on 18 Nov 2026.

Performance Over six months the shares fell 25.9%, against -21.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 9.0% over the last twelve months (peer median +3.4%); the operating margin is 13.4% (peer median -10.6%).

Valuation It trades at 6.3× forward earnings against a peer median of 17.8× (cheapest of 7).

Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -23 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.7 points above its cost of capital (6.9% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 81001060.KS 77
Six months, rebased to 100: JW Pharmaceutical against the median of its 20 peers (local-currency closes).

JW Pharmaceutical financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩833B₩775B₩719B₩749B₩684B
Revenue growth—+8%-4%+9%—
Gross profit₩397B₩359B₩323B₩336B₩288B
EBITDA₩131B₩107B₩102B₩119B₩77.3B
Net income₩87.0B₩58.3B₩61.7B₩35.1B₩30.3B
Free cash flow₩106B₩84.6B₩71.1B₩59.9B₩46.8B
Capital expenditure₩29.6B₩36.1B₩28.1B₩43.0B₩12.4B
Total debt₩69.1B₩54.6B₩91.7B₩170B₩210B

Quarterly statements and history in the cockpit →

JW Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%6010894114TVGN603139048410002728OVIDZOTA600613002923PHAT6881176050776881367871RZLTCTMX000518000788002900001060.KS6-month return →1-month return →
Up and to the right = strong over both horizons. JW Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%10×20×30×40×601089002728PHAT688117605077688136001060.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JW Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%4114002728600613002923688117000788001060.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. JW Pharmaceutical is the large dot.

JW Pharmaceutical competitors and peer comparison

How JW Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JW Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure001060.KSPeer medianRank in peer set
1-month return-7.4%-13.0%6th highest of 21
6-month return-25.9%-21.1%11th highest of 21
Distance from 52-week high-40.9%-51.3%7th highest of 21
Revenue growth (TTM)+9.0%+3.4%9th highest of 19
Operating margin13.4%-10.6%2nd highest of 19
Forward P/E6.3×17.8×cheapest of 7
Growth the price implies (Req g, 7 yrs)-15.4%3.4%least demanding of 7
Growth delivered (Del g)+7.2%+4.7%4th highest of 7
Hurdle (Req g minus delivered)-22.6 pp+1.3 ppleast demanding of 7
ROIC minus cost of capital+11.7 pp-8.2 pp2nd highest of 18
EV / EBITDA4.4×n/a—
Net debt / EBITDA0.1×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%6.3×-15.4%+7.2%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%11.8×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%n/a5.4%+15.3%
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%n/an/an/a
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%n/an/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%28.0×24.4%+8.0%
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%n/an/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%n/an/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%n/a10.6%+1.4%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%n/a1.4%-1.3%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%39.5×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%12.5×-0.2%+14.5%
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%10.3×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%23.1×n/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%n/an/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%n/an/an/a
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%n/an/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%n/a-5.6%-5.6%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%n/an/an/a

Questions

Which companies are JW Pharmaceutical's closest peers?
The cockpit's peer set: Beijing Foyou Pharma (601089.SS), Synmosa Biopharma (4114.TWO), Tevogen (TVGN), Shaanxi Kanghui Pharmaceutical Co (603139.SS), Hyundai Bioscience (048410.KS), Teyi Pharmaceutical (002728.SZ), Ovid Therapeutics (OVID), Zota Health Care (ZOTA.NS).
Is JW Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 6.3× against a peer median of 17.8×, cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has JW Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -25.9% against -21.1% for the median peer; over one year -7.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.